Does Pirfenidone Capsule 267 Mg Interact with Enoxacin?
CDI records a major classification for Pirfenidone Capsule 267 Mg and Enoxacin. The stored summary is: Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment. The mechanism involves cyp1a2 inhibition. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Pirfenidone Capsule 267 Mg Class
- Pyridone
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP1A2 inhibition
What To Tell Your Doctor or Pharmacist
If you are taking Pirfenidone Capsule 267 Mg and your doctor is considering prescribing Enoxacin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider